A Novel Prognostic Model Based on N6-Methyladenosine Regulators Predicts the Prognosis of Acute Myeloid Leukemia

Little is known about the role of N6-methyladenosine (m6A) RNA methylation in the pathogenesis of acute myeloid leukemia (AML). We identified m6A regulators as independent prognostic factors in AML and constructed a prognostic model based on m6A regulators. We performed differential analysis, functional enrichment analysis and protein-protein interaction relationships of the TCGA-LAML cohort. The relationship between m6A methylation and AML was demonstrated by copy number variation, methylation and co-expression analyses. Pathway activity and drug sensitivity analysis revealed possible pathogenic mechanisms of m6A in pan-cancer. Our study elucidates the important role of m6A regulators in the clinical prognosis of AML, and a prognostic model based on m6A regulators can accurately predict overall survival in AML patients.